Recently, genetically proxied inhibition of HMG-CoA reductase but not NPC1L1 and PCSK9 was associated with lower odds of epithelial ovarian cancer in MR study, while no such MR study was currently available for breast cancer and prostate cancer [27]. The gene discussed is PCSK9; the disease is prostate carcinoma.